Cancer in the time of COVID-19: expert opinion on how to adapt current practice
The susceptibility of cancer patients to the adverse outcomes of viral infections is well known from past experiences: influenza increases the risk of hospital admission with respiratory distress four times, and the risk of death 10 times, compared with patients without cancer [1]. This risk is part...
Gespeichert in:
| Veröffentlicht in: | The European respiratory journal 2020-05, Vol.55 (5), p.2000959 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 5 |
| container_start_page | 2000959 |
| container_title | The European respiratory journal |
| container_volume | 55 |
| creator | Raskin, Jo Lebeer, Marnix De Bondt, Charlotte Wener, Reinier Janssens, Annelies van Meerbeeck, Jan P |
| description | The susceptibility of cancer patients to the adverse outcomes of viral infections is well known from past experiences: influenza increases the risk of hospital admission with respiratory distress four times, and the risk of death 10 times, compared with patients without cancer [1]. This risk is particularly elevated in patients with neutropenia or lymphopenia, which is often the case in patients treated with chemotherapy. In Wuhan, China, 1% of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were reported to suffer from cancer, which is more than three times the incidence of cancer in the Chinese population in 2015 [2]. In addition, in 39% of cancer patients (compared with 8% of patients without cancer), transfer to the intensive care unit was necessary, with their illness deteriorating more rapidly (13
versus
43 days to severe event) [2]. Chemotherapy or surgery |
| doi_str_mv | 10.1183/13993003.00959-2020 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7163694</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2391971919</sourcerecordid><originalsourceid>FETCH-LOGICAL-c433t-f1be7f1ec911b636a588a4f77f858f9be3eb3011198664c5c144ec1ec5a2a4ad3</originalsourceid><addsrcrecordid>eNpVUctKBDEQDKLo-vgCQXL0Mpqenlc8CLI-YWEv6jVksj1uZHcyZrI-_t6Mq6IQOtBdVV10MXYI4gSgwlNAKVEIPBFC5jJJRSo22GjoJkN7k42EFJiAxGKH7fb9sxBQZAjbbAfTVMqqKEZsOtatIc9ty8OceLBL4q7h4-nj3WWknnF678gH7jrbWtfy-ObujQfH9Ux3gZuV99QG3nltgjW0z7Yavejp4PvfYw_XV_fj22QyvbkbX0wSkyGGpIGaygbISIC6wELnVaWzpiybKq8aWRNSjQIABpeZyQ1kGZmIz3WqMz3DPXa-1u1W9ZJmJnrweqE6b5fafyinrfo_ae1cPblXVUJcJ7MocPwt4N3LivqglrY3tFjoltyqVylKkCXEEqG4hhrv-t5T87sGhBqiUD9RqK8o1BBFZB39dfjL-bk9fgJ9hYP_</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2391971919</pqid></control><display><type>article</type><title>Cancer in the time of COVID-19: expert opinion on how to adapt current practice</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Raskin, Jo ; Lebeer, Marnix ; De Bondt, Charlotte ; Wener, Reinier ; Janssens, Annelies ; van Meerbeeck, Jan P</creator><creatorcontrib>Raskin, Jo ; Lebeer, Marnix ; De Bondt, Charlotte ; Wener, Reinier ; Janssens, Annelies ; van Meerbeeck, Jan P</creatorcontrib><description>The susceptibility of cancer patients to the adverse outcomes of viral infections is well known from past experiences: influenza increases the risk of hospital admission with respiratory distress four times, and the risk of death 10 times, compared with patients without cancer [1]. This risk is particularly elevated in patients with neutropenia or lymphopenia, which is often the case in patients treated with chemotherapy. In Wuhan, China, 1% of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were reported to suffer from cancer, which is more than three times the incidence of cancer in the Chinese population in 2015 [2]. In addition, in 39% of cancer patients (compared with 8% of patients without cancer), transfer to the intensive care unit was necessary, with their illness deteriorating more rapidly (13
versus
43 days to severe event) [2]. Chemotherapy or surgery <1 month before was an important risk factor (OR 5.34, p=0.0026).
Our current thoracic oncology practice could/should be adapted to the COVID-19 pandemic by reducing time in hospital and patient contacts with healthcare workers, whilst maintaining quality of care. This letter offers expert advice on how to do so.
https://bit.ly/2JR2IoT</description><identifier>ISSN: 0903-1936</identifier><identifier>EISSN: 1399-3003</identifier><identifier>DOI: 10.1183/13993003.00959-2020</identifier><identifier>PMID: 32299866</identifier><language>eng</language><publisher>England: European Respiratory Society</publisher><subject>Agora ; Belgium ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - radiotherapy ; Carcinoma, Non-Small-Cell Lung - surgery ; Coronavirus Infections - epidemiology ; Disease Susceptibility ; France ; Humans ; Lung Neoplasms - drug therapy ; Mesothelioma - drug therapy ; Neoplasms - drug therapy ; Neoplasms - radiotherapy ; Neoplasms - surgery ; Neoplasms - therapy ; Neoplasms, Glandular and Epithelial - drug therapy ; Pandemics ; Pneumonia, Viral - epidemiology ; Practice Guidelines as Topic ; Prognosis ; Small Cell Lung Carcinoma - drug therapy ; Small Cell Lung Carcinoma - radiotherapy ; Societies, Medical ; Telemedicine ; Thymus Neoplasms - drug therapy ; United Kingdom ; Videoconferencing</subject><ispartof>The European respiratory journal, 2020-05, Vol.55 (5), p.2000959</ispartof><rights>Copyright ©ERS 2020 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c433t-f1be7f1ec911b636a588a4f77f858f9be3eb3011198664c5c144ec1ec5a2a4ad3</citedby><cites>FETCH-LOGICAL-c433t-f1be7f1ec911b636a588a4f77f858f9be3eb3011198664c5c144ec1ec5a2a4ad3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,777,781,882,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32299866$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Raskin, Jo</creatorcontrib><creatorcontrib>Lebeer, Marnix</creatorcontrib><creatorcontrib>De Bondt, Charlotte</creatorcontrib><creatorcontrib>Wener, Reinier</creatorcontrib><creatorcontrib>Janssens, Annelies</creatorcontrib><creatorcontrib>van Meerbeeck, Jan P</creatorcontrib><title>Cancer in the time of COVID-19: expert opinion on how to adapt current practice</title><title>The European respiratory journal</title><addtitle>Eur Respir J</addtitle><description>The susceptibility of cancer patients to the adverse outcomes of viral infections is well known from past experiences: influenza increases the risk of hospital admission with respiratory distress four times, and the risk of death 10 times, compared with patients without cancer [1]. This risk is particularly elevated in patients with neutropenia or lymphopenia, which is often the case in patients treated with chemotherapy. In Wuhan, China, 1% of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were reported to suffer from cancer, which is more than three times the incidence of cancer in the Chinese population in 2015 [2]. In addition, in 39% of cancer patients (compared with 8% of patients without cancer), transfer to the intensive care unit was necessary, with their illness deteriorating more rapidly (13
versus
43 days to severe event) [2]. Chemotherapy or surgery <1 month before was an important risk factor (OR 5.34, p=0.0026).
Our current thoracic oncology practice could/should be adapted to the COVID-19 pandemic by reducing time in hospital and patient contacts with healthcare workers, whilst maintaining quality of care. This letter offers expert advice on how to do so.
https://bit.ly/2JR2IoT</description><subject>Agora</subject><subject>Belgium</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - radiotherapy</subject><subject>Carcinoma, Non-Small-Cell Lung - surgery</subject><subject>Coronavirus Infections - epidemiology</subject><subject>Disease Susceptibility</subject><subject>France</subject><subject>Humans</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Mesothelioma - drug therapy</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - radiotherapy</subject><subject>Neoplasms - surgery</subject><subject>Neoplasms - therapy</subject><subject>Neoplasms, Glandular and Epithelial - drug therapy</subject><subject>Pandemics</subject><subject>Pneumonia, Viral - epidemiology</subject><subject>Practice Guidelines as Topic</subject><subject>Prognosis</subject><subject>Small Cell Lung Carcinoma - drug therapy</subject><subject>Small Cell Lung Carcinoma - radiotherapy</subject><subject>Societies, Medical</subject><subject>Telemedicine</subject><subject>Thymus Neoplasms - drug therapy</subject><subject>United Kingdom</subject><subject>Videoconferencing</subject><issn>0903-1936</issn><issn>1399-3003</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVUctKBDEQDKLo-vgCQXL0Mpqenlc8CLI-YWEv6jVksj1uZHcyZrI-_t6Mq6IQOtBdVV10MXYI4gSgwlNAKVEIPBFC5jJJRSo22GjoJkN7k42EFJiAxGKH7fb9sxBQZAjbbAfTVMqqKEZsOtatIc9ty8OceLBL4q7h4-nj3WWknnF678gH7jrbWtfy-ObujQfH9Ux3gZuV99QG3nltgjW0z7Yavejp4PvfYw_XV_fj22QyvbkbX0wSkyGGpIGaygbISIC6wELnVaWzpiybKq8aWRNSjQIABpeZyQ1kGZmIz3WqMz3DPXa-1u1W9ZJmJnrweqE6b5fafyinrfo_ae1cPblXVUJcJ7MocPwt4N3LivqglrY3tFjoltyqVylKkCXEEqG4hhrv-t5T87sGhBqiUD9RqK8o1BBFZB39dfjL-bk9fgJ9hYP_</recordid><startdate>20200501</startdate><enddate>20200501</enddate><creator>Raskin, Jo</creator><creator>Lebeer, Marnix</creator><creator>De Bondt, Charlotte</creator><creator>Wener, Reinier</creator><creator>Janssens, Annelies</creator><creator>van Meerbeeck, Jan P</creator><general>European Respiratory Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20200501</creationdate><title>Cancer in the time of COVID-19: expert opinion on how to adapt current practice</title><author>Raskin, Jo ; Lebeer, Marnix ; De Bondt, Charlotte ; Wener, Reinier ; Janssens, Annelies ; van Meerbeeck, Jan P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c433t-f1be7f1ec911b636a588a4f77f858f9be3eb3011198664c5c144ec1ec5a2a4ad3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Agora</topic><topic>Belgium</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - radiotherapy</topic><topic>Carcinoma, Non-Small-Cell Lung - surgery</topic><topic>Coronavirus Infections - epidemiology</topic><topic>Disease Susceptibility</topic><topic>France</topic><topic>Humans</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Mesothelioma - drug therapy</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - radiotherapy</topic><topic>Neoplasms - surgery</topic><topic>Neoplasms - therapy</topic><topic>Neoplasms, Glandular and Epithelial - drug therapy</topic><topic>Pandemics</topic><topic>Pneumonia, Viral - epidemiology</topic><topic>Practice Guidelines as Topic</topic><topic>Prognosis</topic><topic>Small Cell Lung Carcinoma - drug therapy</topic><topic>Small Cell Lung Carcinoma - radiotherapy</topic><topic>Societies, Medical</topic><topic>Telemedicine</topic><topic>Thymus Neoplasms - drug therapy</topic><topic>United Kingdom</topic><topic>Videoconferencing</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Raskin, Jo</creatorcontrib><creatorcontrib>Lebeer, Marnix</creatorcontrib><creatorcontrib>De Bondt, Charlotte</creatorcontrib><creatorcontrib>Wener, Reinier</creatorcontrib><creatorcontrib>Janssens, Annelies</creatorcontrib><creatorcontrib>van Meerbeeck, Jan P</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The European respiratory journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Raskin, Jo</au><au>Lebeer, Marnix</au><au>De Bondt, Charlotte</au><au>Wener, Reinier</au><au>Janssens, Annelies</au><au>van Meerbeeck, Jan P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cancer in the time of COVID-19: expert opinion on how to adapt current practice</atitle><jtitle>The European respiratory journal</jtitle><addtitle>Eur Respir J</addtitle><date>2020-05-01</date><risdate>2020</risdate><volume>55</volume><issue>5</issue><spage>2000959</spage><pages>2000959-</pages><issn>0903-1936</issn><eissn>1399-3003</eissn><abstract>The susceptibility of cancer patients to the adverse outcomes of viral infections is well known from past experiences: influenza increases the risk of hospital admission with respiratory distress four times, and the risk of death 10 times, compared with patients without cancer [1]. This risk is particularly elevated in patients with neutropenia or lymphopenia, which is often the case in patients treated with chemotherapy. In Wuhan, China, 1% of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were reported to suffer from cancer, which is more than three times the incidence of cancer in the Chinese population in 2015 [2]. In addition, in 39% of cancer patients (compared with 8% of patients without cancer), transfer to the intensive care unit was necessary, with their illness deteriorating more rapidly (13
versus
43 days to severe event) [2]. Chemotherapy or surgery <1 month before was an important risk factor (OR 5.34, p=0.0026).
Our current thoracic oncology practice could/should be adapted to the COVID-19 pandemic by reducing time in hospital and patient contacts with healthcare workers, whilst maintaining quality of care. This letter offers expert advice on how to do so.
https://bit.ly/2JR2IoT</abstract><cop>England</cop><pub>European Respiratory Society</pub><pmid>32299866</pmid><doi>10.1183/13993003.00959-2020</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0903-1936 |
| ispartof | The European respiratory journal, 2020-05, Vol.55 (5), p.2000959 |
| issn | 0903-1936 1399-3003 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7163694 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Agora Belgium Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - radiotherapy Carcinoma, Non-Small-Cell Lung - surgery Coronavirus Infections - epidemiology Disease Susceptibility France Humans Lung Neoplasms - drug therapy Mesothelioma - drug therapy Neoplasms - drug therapy Neoplasms - radiotherapy Neoplasms - surgery Neoplasms - therapy Neoplasms, Glandular and Epithelial - drug therapy Pandemics Pneumonia, Viral - epidemiology Practice Guidelines as Topic Prognosis Small Cell Lung Carcinoma - drug therapy Small Cell Lung Carcinoma - radiotherapy Societies, Medical Telemedicine Thymus Neoplasms - drug therapy United Kingdom Videoconferencing |
| title | Cancer in the time of COVID-19: expert opinion on how to adapt current practice |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T13%3A05%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cancer%20in%20the%20time%20of%20COVID-19:%20expert%20opinion%20on%20how%20to%20adapt%20current%20practice&rft.jtitle=The%20European%20respiratory%20journal&rft.au=Raskin,%20Jo&rft.date=2020-05-01&rft.volume=55&rft.issue=5&rft.spage=2000959&rft.pages=2000959-&rft.issn=0903-1936&rft.eissn=1399-3003&rft_id=info:doi/10.1183/13993003.00959-2020&rft_dat=%3Cproquest_pubme%3E2391971919%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2391971919&rft_id=info:pmid/32299866&rfr_iscdi=true |